Advestra advises joint global coordinators on BioVersys’ IPO
Advestra advised Citigroup, UBS and Stifel Europe in connection with ther joint global coordination role in BioVersys’ IPO.
The context
BioVersys specialises in the identification, development and commercialization phases of novel antibacterial products for life-threatening infections caused by multi-drug resistant (MDR) bacteria. Beyond its home biotech lab of Basel, BioVersys is also operative in Lille (France), Delaware (United States), and Guangzhou (China).
On February 7 2025, BioVersys’s share trading officially kicked-off. The IPO leading to that day comprised a primary offering targeting gross proceeds of CHF 80 m , including an over-allotment option targeting gross proceeds of CHF 5 m.
All global coordination and bookrunning aspects of the IPO were jointly managed by Citigroup, UBS and Stifel Europe, with Advestra acting as their legal advisor.
Mirabaud & Cie and Octavian were the appointed selling agents on the deal.
The team
Partner Annette Weber (pictured) led the Advestra team alongside partner Sandro Fehlmann, associate Valérie Bayard and junior associate Luca Schmid (all capital markets). Partner Céline Martin handled all taxation aspects on the matter.
